Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cells and PRP vs Standard Therapy in Organic Erectile Dysfunction
NCT07544537Phase 2Active, not recruiting
- Sponsor
- National Scientific Medical Center
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone-marrow mesenchymal stem cells and autologous platelet-rich plasma in erectile dysfunction (ED) (5 arms), sponsored by National Scientific Medical Center. Primary endpoint: International Index of Erectile Function Score at 12 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
autologous bone-marrow mesenchymal stem cellsautologous platelet-rich plasma
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT07544537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544537.